Beam Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Beam Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BEAM
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201.
CEOJohn Evans
CEOJohn Evans
Employees483
Employees483
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2017
Founded2017
Employees483
Employees483
BEAM Key Statistics
Market cap2.60B
Market cap2.60B
Price-Earnings ratio-5.77
Price-Earnings ratio-5.77
Dividend yield—
Dividend yield—
Average volume1.69M
Average volume1.69M
High today$26.07
High today$26.07
Low today$26.07
Low today$26.07
Open price$26.82
Open price$26.82
Volume6.68K
Volume6.68K
52 Week high$35.25
52 Week high$35.25
52 Week low$13.53
52 Week low$13.53
Stock Snapshot
The current Beam Therapeutics(BEAM) stock price is $26.07, with a market capitalization of 2.6B. The stock trades at a price-to-earnings (P/E) ratio of -5.77.
On 2025-12-18, Beam Therapeutics(BEAM) stock traded between a low of $26.07 and a high of $26.07. Shares are currently priced at $26.07, which is 0.0% above the low and 0.0% below the high.
The Beam Therapeutics(BEAM)'s current trading volume is 6.68K, compared to an average daily volume of 1.69M.
During the past year, Beam Therapeutics(BEAM) stock moved between $13.53 at its lowest and $35.25 at its peak.
During the past year, Beam Therapeutics(BEAM) stock moved between $13.53 at its lowest and $35.25 at its peak.
Analyst ratings
88%
of 17 ratingsBuy
88.2%
Hold
11.8%
Sell
0%
People also own
Based on the portfolios of people who own BEAM. This list is generated using Robinhood data, and it’s not a recommendation.